collection
MENU ▼
Read by QxMD icon Read
search

IBD

shared collection
188 papers 100 to 500 followers
By Jeff Bank Internal Medicine R2 at the University of Utah
https://www.readbyqxmd.com/read/28195179/fostering-collaboration-through-creation-of-an-ibd-learning-health-system
#1
Lisa C Johnson, Gil Y Melmed, Eugene C Nelson, Megan M Holthoff, S Alandra Weaver, Tamara S Morgan, Corey A Siegel
No abstract text is available yet for this article.
February 14, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28147377/case-report-acute-flair-of-ulcerative-colitis-during-pregnancy-is-still-a-major-problem
#2
Marijana Protic, Srdjan Markovic, Dino Tarabar
Although severe flare of ulcerative colitis (UC) is uncommon, it significantly increases the risk of preterm delivery, low birth weight and other adverse fetal outcomes. It is critical to optimize aggressive medical treatment with both mother and fetal health. Here, we present a case of a 30-year-old woman with a severe flare of UC at the 16th gestational week. The diagnosis of extensive UC was established 8 years ago. From the time she was diagnosed, she had 5 moderate flares successfully treated with oral and topical mesalamine...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28071656/acg-clinical-guideline-preventive-care-in-inflammatory-bowel-disease
#3
Francis A Farraye, Gil Y Melmed, Gary R Lichtenstein, Sunanda V Kane
Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy...
January 10, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28117363/increased-risk-of-gallstone-disease-following-colectomy-for-ulcerative-colitis
#4
Anders Mark-Christensen, Søren Brandsborg, Søren Laurberg, Niels Johansen, Jørn Helmut Pachler, Ole Thorlacius-Ussing, Mie Dilling Kjær, Niels Qvist, Louise Preisler, Jens Hillingsø, Jacob Rosenberg, Peter Jepsen
OBJECTIVES: Biochemical studies suggest that patients who have had a colectomy or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) are at an increased risk of developing gallstone disease, but epidemiological studies are lacking. We evaluated the risk of gallstone disease following colectomy and IPAA. METHODS: Individuals who had a colectomy were identified from a national cohort of patients with ulcerative colitis (UC), and controls without colectomy were sampled from within the same cohort, matching on gender, calendar year, and year of birth...
January 24, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28045023/meta-analytic-bayesian-model-for-differentiating-intestinal-tuberculosis-from-crohn-s-disease
#5
REVIEW
Julajak Limsrivilai, Andrew B Shreiner, Ananya Pongpaibul, Charlie Laohapand, Rewat Boonanuwat, Nonthalee Pausawasdi, Supot Pongprasobchai, Sathaporn Manatsathit, Peter D R Higgins
OBJECTIVES: Distinguishing intestinal tuberculosis (ITB) from Crohn's disease (CD) is difficult, although studies have reported clinical, endoscopic, imaging, and laboratory findings that help to differentiate these two diseases. We aimed to produce estimates of the predictive power of these findings and construct a comprehensive model to predict the probability of ITB vs. CD. METHODS: A systematic literature search for studies differentiating ITB from CD was conducted in MEDLINE, PUBMED, and EMBASE from inception until September 2015...
January 3, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27914655/crohn-s-disease
#6
REVIEW
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, with increasing incidence worldwide. Crohn's disease might result from a complex interplay between genetic susceptibility, environmental factors, and altered gut microbiota, leading to dysregulated innate and adaptive immune responses. The typical clinical scenario is a young patient presenting with abdominal pain, chronic diarrhoea, weight loss, and fatigue. Assessment of disease extent and of prognostic factors for complications is paramount to guide therapeutic decisions...
November 30, 2016: Lancet
https://www.readbyqxmd.com/read/27914657/ulcerative-colitis
#7
REVIEW
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel
Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings...
November 30, 2016: Lancet
https://www.readbyqxmd.com/read/27960091/inflammatory-bowel-disease-2017-innovations-and-changing-paradigms
#8
Jean-Frederic Colombel, Uma Mahadevan
No abstract text is available yet for this article.
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27714831/vedolizumab-provides-clinical-benefit-over-1-year-in-patients-with-active-inflammatory-bowel-disease-a-prospective-multicenter-observational-study
#9
A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, F Hartmann, M F Neurath, J Maul, J C Preiss, R Schmelz, B Siegmund, H Schulze, N Teich, U von Arnim, D C Baumgart, C Schmidt
BACKGROUND: Vedolizumab, a monoclonal antibody targeting the α4β7-integrin, is effective in inducing and maintaining clinical remission in Crohn's disease and ulcerative colitis according to randomised clinical trials. AIM: To determine the long-term effectiveness of vedolizumab in a real-world clinical setting. METHODS: This observational registry assessed the clinical outcome in patients treated with vedolizumab for clinically active Crohn's disease (n = 67) or ulcerative colitis (n = 60)...
December 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888668/inflammatory-bowel-disease-a-global-disease-that-needs-a%C3%A2-broader-ensemble-of-populations
#10
EDITORIAL
Andre Franke
No abstract text is available yet for this article.
January 2017: Gastroenterology
https://www.readbyqxmd.com/read/27660341/3rd-european-evidence-based-consensus-on-the-diagnosis-and-management-of-crohn-s-disease-2016-part-1-diagnosis-and-medical-management
#11
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik, Florian Rieder, Sven Almer, Alessandro Armuzzi, Marcus Harbord, Jost Langhorst, Miquel Sans, Yehuda Chowers, Gionata Fiorino, Pascal Juillerat, Gerassimos J Mantzaris, Fernando Rizzello, Stephan Vavricka, Paolo Gionchetti
This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016]...
January 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27845055/is-stem-cell-therapy-ready-for-prime-time-in-treatment-of-inflammatory-bowel-diseases
#12
Christopher J Hawkey, Daniel W Hommes
Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively. Will these highly advanced techniques be available only for select patients, at specialized centers, or is further clinical development justified, with the aim of offering widespread, more definitive therapeutic options for often very difficult to treat disease? Patients with CD who are eligible for HSCT have typically been failed by most approved therapies, have undergone multiple surgeries, and have coped with years of disease activity and poor quality of life...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27720839/mechanisms-management-and-treatment-of-fibrosis-in-patients-with-inflammatory-bowel-diseases
#13
Florian Rieder, Claudio Fiocchi, Gerhard Rogler
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. Inflammatory bowel diseases-associated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the antifibrotic approaches that may become available...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27548724/any-future-for-fecal-microbiota-transplantation-as-treatment-strategy-for-inflammatory-bowel-diseases
#14
Patrizia Kump, Christoph Högenauer
Fecal microbiota transplantation (FMT) is a novel therapeutic procedure aiming at restoring a normal intestinal microbiota by application of fecal microorganisms from a healthy subject into the gastrointestinal tract of a patient. FMT is the most effective treatment for recurrent Clostridium difficile infections (CDI). These infections also occur in patients with inflammatory bowel diseases (IBDs), where case series demonstrated a successful treatment of CDI by FMT in 83-92% of patients. The effect of FMT on the activity of IBD has mainly been investigated in ulcerative colitis (UC) patients, including 3 randomized controlled trials...
2016: Digestive Diseases
https://www.readbyqxmd.com/read/27780712/lessons-learned-from-trials-targeting-cytokine-pathways-in%C3%A2-patients-with-inflammatory-bowel-diseases
#15
Clara Abraham, Parambir S Dulai, Séverine Vermeire, William J Sandborn
Insights into the pathogenesis of inflammatory bowel diseases (IBDs) have provided important information for the development of therapeutics. Levels of interleukin 23 (IL23) and T-helper (Th) 17 cell pathway molecules are increased in inflamed intestinal tissues of patients with IBD. Loss-of-function variants of the IL23-receptor gene (IL23R) protect against IBD, and, in animals, blocking IL23 reduces the severity of colitis. These findings indicated that the IL23 and Th17 cell pathways might be promising targets for the treatment of IBD...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27793606/diet-as-a-trigger-or-therapy-for-inflammatory-bowel-diseases
#16
James D Lewis, Maria T Abreu
The most common question asked by patients with inflammatory bowel disease (IBD) is, "Doctor, what should I eat?" Findings from epidemiology studies have indicated that diets high in animal fat and low in fruits and vegetables are the most common pattern associated with an increased risk of IBD. Low levels of vitamin D also appear to be a risk factor for IBD. In murine models, diets high in fat, especially saturated animal fats, also increase inflammation, whereas supplementation with omega 3 long-chain fatty acids protect against intestinal inflammation...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27793607/understanding-and-preventing-the-global-increase-of-inflammatory-bowel-disease
#17
Gilaad G Kaplan, Siew C Ng
The inflammatory bowel diseases (IBDs) are contemporary conditions of industrialized societies. The prevalence of IBD continues to increase steadily in Western countries, and newly industrialized countries have a rapidly increasing incidence. The global spread of IBD appears to associate with Westernization of diets and environments, which affects the intestinal microbiome and increases the risk of IBD in genetically susceptible individuals. It is important to increase our understanding of these events to slow progression of IBD...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27742763/molecular-classification-of-crohn-s-disease-reveals-two-clinically-relevant-subtypes
#18
Matthew Weiser, Jeremy M Simon, Bharati Kochar, Adelaide Tovar, Jennifer W Israel, Adam Robinson, Gregory R Gipson, Matthew S Schaner, Hans H Herfarth, R Balfour Sartor, Dermot P B McGovern, Reza Rahbar, Timothy S Sadiq, Mark J Koruda, Terrence S Furey, Shehzad Z Sheikh
OBJECTIVE: The clinical presentation and course of Crohn's disease (CD) is highly variable. We sought to better understand the cellular and molecular mechanisms that guide this heterogeneity, and characterise the cellular processes associated with disease phenotypes. DESIGN: We examined both gene expression and gene regulation (chromatin accessibility) in non-inflamed colon tissue from a cohort of adult patients with CD and control patients. To support the generality of our findings, we analysed previously published expression data from a large cohort of treatment-naïve paediatric CD and control ileum...
October 14, 2016: Gut
https://www.readbyqxmd.com/read/27769809/drug-safety-and-risk-of-adverse-outcomes-for-pregnant-patients-with-inflammatory-bowel-disease
#19
Uma Mahadevan, Ryan A McConnell, Christina D Chambers
The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication...
February 2017: Gastroenterology
https://www.readbyqxmd.com/read/27743873/complementary-and-alternative-medicines-used-by-patients-with%C3%A2-inflammatory-bowel-diseases
#20
Adam S Cheifetz, Robert Gianotti, Raphael Luber, Peter R Gibson
Patients and physicians often have many questions regarding the role of complementary and alternative medicines (CAMs), or nonallopathic therapies, for inflammatory bowel diseases (IBDs). CAMs of various forms are used by more than half of patients with IBD during some point in their disease course. We summarize the available evidence for the most commonly used and discussed CAMs. We discuss evidence for the effects of herbs (such as cannabis and curcumin), probiotics, acupuncture, exercise, and mind-body therapy...
February 2017: Gastroenterology
label_collection
label_collection
2221
1
2
2016-10-21 05:57:11
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"